Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group.
Sweetenham JW, Santini G, Qian W, Guelfi M, Schmitz N, Simnett S, Nagler A, Holte H, Kvaloy S, Bruzzi P, Goldstone AH. Sweetenham JW, et al. J Clin Oncol. 2001 Jun 1;19(11):2927-36. doi: 10.1200/JCO.2001.19.11.2927. J Clin Oncol. 2001. PMID: 11387366 Clinical Trial.
High-dose therapy and autologous bone marrow transplantation in first complete remission for adult patients with high-grade non-Hodgkin's lymphoma: the EBMT experience. Lymphoma Working Party of the European Group for Bone Marrow Transplantation.
Sweetenham JW, Proctor SJ, Blaise D, De Laurenzi A, Pearce R, Taghipour G, Goldstone AH, Laurenzi A [corrected to De Laurenzi A]. Sweetenham JW, et al. Ann Oncol. 1994;5 Suppl 2:155-9. doi: 10.1093/annonc/5.suppl_2.s155. Ann Oncol. 1994. PMID: 7515646
Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma--outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation.
Sweetenham JW, Pearce R, Taghipour G, Blaise D, Gisselbrecht C, Goldstone AH. Sweetenham JW, et al. J Clin Oncol. 1996 Sep;14(9):2465-72. doi: 10.1200/JCO.1996.14.9.2465. J Clin Oncol. 1996. PMID: 8823324
High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Sweetenham JW, Taghipour G, Milligan D, Blystad AK, Caballero D, Fassas A, Goldstone AH. Sweetenham JW, et al. Bone Marrow Transplant. 1997 Nov;20(9):745-52. doi: 10.1038/sj.bmt.1700963. Bone Marrow Transplant. 1997. PMID: 9384476 Clinical Trial.
High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party.
Sweetenham JW, Carella AM, Taghipour G, Cunningham D, Marcus R, Della Volpe A, Linch DC, Schmitz N, Goldstone AH. Sweetenham JW, et al. J Clin Oncol. 1999 Oct;17(10):3101-9. doi: 10.1200/JCO.1999.17.10.3101. J Clin Oncol. 1999. PMID: 10506605
Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.
Bierman PJ, Sweetenham JW, Loberiza FR Jr, Taghipour G, Lazarus HM, Rizzo JD, Schmitz N, van Besien K, Vose JM, Horowitz M, Goldstone A; Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Bierman PJ, et al. Among authors: sweetenham jw. J Clin Oncol. 2003 Oct 15;21(20):3744-53. doi: 10.1200/JCO.2003.08.054. Epub 2003 Sep 8. J Clin Oncol. 2003. PMID: 12963703
149 results